The estimated Net Worth of Arundathy N. Pandite is at least $979 Tysiąc dollars as of 10 August 2021. Dr Pandite owns over 4,259 units of Shattuck Labs stock worth over $395,999 and over the last 4 years he sold STTK stock worth over $0. In addition, he makes $583,002 as Chief Medical Officer at Shattuck Labs.
Dr has made over 2 trades of the Shattuck Labs stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 4,259 units of STTK stock worth $43 on 10 August 2021.
The largest trade he's ever made was exercising 4,259 units of Shattuck Labs stock on 10 August 2021 worth over $43. On average, Dr trades about 586 units every 22 days since 2020. As of 10 August 2021 he still owns at least 106,166 units of Shattuck Labs stock.
You can see the complete history of Dr Pandite stock trades at the bottom of the page.
Dr. Arundathy Nirmalini Pandite M.B.A., M.D. is the Chief Medical Officer at Shattuck Labs.
As the Chief Medical Officer of Shattuck Labs, the total compensation of Dr D at Shattuck Labs is $583,002. There are no executives at Shattuck Labs getting paid more.
Dr D is 62, he's been the Chief Medical Officer of Shattuck Labs since . There are no older and 7 younger executives at Shattuck Labs.
Arundathy's mailing address filed with the SEC is C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN, TX, 78701.
Over the last 4 years, insiders at Shattuck Labs have traded over $14,634,250 worth of Shattuck Labs stock and bought 3,526,605 units worth $60,008,520 . The most active insiders traders include Group, Llc Green Jeremy Red..., Clay B Siegall oraz Josiah Hornblower. On average, Shattuck Labs executives and independent directors trade stock every 25 days with the average trade being worth of $300,381. The most recent stock trade was executed by Tyler Brous on 27 June 2024, trading 8,416 units of STTK stock currently worth $32,738.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Shattuck Labs executives and other stock owners filed with the SEC include: